Everolimus mTOR inhibitor

Certican - Afinitor - RAD001 - RAD 001 - 40-O-(2-hydroxyethyl)-rapamycin - SDZ-RAD - SDZ RAD



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - mTOR inhibitor in all type of patients - mTOR inhibitor in patients recurring or progressing after prior endocrine therapy - mTOR inhibitor in HR+ HER2- - mTOR inhibitor in patient trastuzumab-resistant, and previously treated by taxanes

BOLERO-2, 2011everolimus + exemestaneexemestane alone724 (485/239) Confirmatory NCT00863655
TAMRAD , 2012everolimus + tamoxifentamoxifen alone111 (54/57) Exploratory NCT01298713
BOLERO-3, 2014everolimus + trastuzumab + vinorelbinetrastuzumab + vinorelbine alone569 (284/285) Confirmatory NCT01007942

Renal-cell carcinoma (advanced) - mTOR inhibitor in all type of patients

RECORD-1, 2008everolimusplacebo410 (272/138) NCT00410124
RECORD 3, 2014everolimussunitinib471 (238/233) NCT00903175